آداب معاشرت، سورة حجرات کی گیارهویں اور بارهویں آیات کے تناظر میں

Dr. Shari'ati is a revolutionary intellectual personality of this century. He regarded Islamic values ​​as the guarantee of salvation and success for humanity. He sought to mobilize and revive frozen Islamic ideas. That is, tried to bring the Islamic concept out of the boundaries of formal and congested boundaries into common and general thoughts. Dr. Shari'ati also presented a unique view that divine Imam transcends than worldly governments and this divine leadership cannot be determined by (Shuraiet). Rather, it can be diagnosed by an obvious reason (Nass). This doctrine of Dr. Shari'ati is contrary to the ideology of the Sunni and the Shi'ite’s concept of Imamat and Khilafat because the Sunni sect believes that Khilafat Or Imamt should be determine by the Shurait (Council) and Shiites by the will(Nass). According to Dr. Shairathi, Imamat cannot be determining through Shourait or Nass but it can be identified by the superior attributes of the Imam. He believes that Imamat is not an external factor which can gain by attainment or by choice; rather, it is an Inherit object.  In accepting this doctrine of Dr. Shari'ati, than the Imamat becomes a part of the system of naturalism (Takveeni). That makes the Imamat not a model process for humanity. So it would be a complicated issue to discuss and discover either the theory of Dr. Shari'ati is a applicable idea of Imamat or it is a just onlyu idialogy which cannot be practiced. The dissertation has been written to examine the reality of these two cases either Imamat is inherit case or it can be attainment case through Shouriat or Nass.   

Androgen Receptor Expression and Associated Clinico-Pathologic Features in Primary Breast Cancer from Kenya

Introduction: Breast cancer is a heterogeneous group of diseases classified into various subtypes according to clinical, histological and molecular features as well as by the expression of prognostic and predictive biomarkers. New biomarkers are being studied which may be therapeutic targets in various breast cancer subtypes particularly triple-negative breast cancer. Recent studies show that androgen receptor (AR) expression can be used as a prognostic marker and there is evidence that anti-androgen therapy may be beneficial in oestrogen receptor negative breast cancer. Retrospective studies show that patients with breast cancers co-expressing androgen receptor and oestrogen receptor have a favourable prognosis and improved survival. On the other hand, oestrogen receptor-negative breast cancers which express the androgen receptor in the presence of the human epidermal growth factor-2 (HER2) over-expression are associated with an unfavourable prognosis. In addition there may be regional or even racial differences in the expression of the AR in breast cancer. The objective of this study was, therefore, to determine AR expression in breast cancers from Kenya and secondarily, to determine the association of AR expression with prognostic and predictive clinico-pathologic factors. Materials and Methods: The study was nested within a larger study based at AKUHN which is exploring the prevalence of triple-negative breast cancer in Kenya. Tissue blocks from 222 breast cancer specimens collected prospectively from September 2012 to March 2014 within the larger study were analysed for the presence of the androgen receptor. Tumour blocks were stained for AR on automated IHC platform. Nuclear staining of >10% was used as the cut-off for a positive AR stain. Clinical pathological features, including the ER/PR/HER2 status, were captured from data recorded in the larger study. Results: Of the total 222 cases of breast cancer analyzed for the androgen receptor, 78.8% were found to be positive for AR expression (confidence interval 72.86 – 84.01). A third of the triple-negative breast cancer cases (33%) and 94% of HER2 subtype breast cancer cases were positive for androgen receptor expression. Androgen receptor expression was significantly associated with estrogen receptor expression (p = 0.000001) and Her2 subtype of breast cancer (p = 0.04). Androgen receptor expression followed the age distribution of the sample population and tended to be inversely related to tumour grade. However these findings were not statistically significant. No association was found between androgen receptor expression, tumour stage, lymph node status or specimen type. Conclusions: The androgen receptor is expressed in 79% of